ASRT Stock Recent News

Assertio Holdings has undergone a significant transformation in its business model, reducing debt and exiting the opioid business. The company's recent performance has shown strong growth, with increased net product sales and improved gross margin. Assertio's stock is currently undervalued, trading at a significant discount, and has the potential for future growth and a turnaround.

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Assertio (NASDAQ: ASRT ) stock is falling hard on Friday after the pharmaceutical company released its Q2 earnings report. Assertio disappointed investors with its adjusted earnings per share of 19 cents.

The stock is down 33% from its 52-week high. Q2 revenue estimates are low. Lead product's use may be expanding.

Spectrum stockholders will receive contingent value rights, too, along with Assertio shares. The rewards are payable on achievement of 2024 and 2025 sales levels from Spectrum's lead drug. Rolvedon has already reached the first (hardest) target in Q1 without the help of a J-Code that took effect at the beginning of Q2.

The Supreme Court recently nullified the Biden administration's proposed student loan forgiveness program in a 6-3 ruling. Seen as overreaching the authority of the executive branch, this program intended to forgive nearly $430 billion in loans.

Assertio is a late-stage pharmaceutical company that has shown significant growth and cost savings under new leadership, focusing on a low-cost, data-driven marketing model. The company's leading product, Indocin, has seen increased sales and a recent 5x market expansion not yet included in company guidance. Assertio ranks in the top 1% of stocks in both value and high-quality momentum.

Share portion of takeover by Assertio Holdings covers the value of the shares plus a merger spread. Contingent value rights on their drug are also included, adding up to $0.20 per share. CVR payout will require aggressive sales growth, but they're effectively free.

Assertio Holdings, a pharmaceutical company, has demonstrated solid financials and growth potential, with a focus on reducing debt levels and increasing cash generation through strategic acquisitions. The company's liquidity position has improved over the past few years, with increasing current and cash ratios indicating a well-managed leverage condition. Despite potential risks such as increasing competition from generics and supply chain vulnerabilities, Assertio's strong financial structures and progress make it a suitable buy-rated stock.